Long-acting hydrogen release system for assisting cell transplantation as well as preparation method and application of long-acting hydrogen release system

By combining magnesium silicide or titanium silicide nanosheets with hydrogels to create a long-lasting hydrogen release system, the problems of maintaining the vitality of transplanted stem cells in the pathological microenvironment and insufficient hydrogen release are solved, achieving ultra-long-term hydrogen supply and significantly improving the cartilage repair effect in osteoarthritis.

CN121313666APending Publication Date: 2026-01-13SHANGHAI JIAOTONG UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202511326170.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-09-17
Publication Date
2026-01-13

AI Technical Summary

Technical Problem

In existing technologies, stem cell transplantation is difficult to maintain its vitality and normal physiological characteristics in vitro, especially in the pathological microenvironment where it rapidly loses its vitality, affecting the treatment effect. Furthermore, the hydrogen release duration of existing hydrolysis hydrogen production materials is insufficient to meet the needs of long-term osteoarthritis treatment.

Method used

Hydrogen-releasing materials with a particle size of 5nm-10μm, such as magnesium silicide or titanium silicide nanosheets, are combined with a hydrogel matrix to form a long-lasting hydrogen-releasing system. This system is prepared by photosensitive crosslinking and other methods and is used to assist in the transplantation of stem cells or chondrocytes, continuously supplying hydrogen to maintain cell viability and directed differentiation.

Benefits of technology

In the harsh pathological microenvironment, the long-acting hydrogen release system effectively maintains the activity of stem cells and chondrocytes and the differentiation potential of hyaline cartilage, significantly improves the cartilage repair efficiency in osteoarthritis, achieves ultra-long-term hydrogen release, extending to 30 or 60 days, and significantly improves the treatment effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121313666A_ABST
    Figure CN121313666A_ABST
Patent Text Reader

Abstract

The invention relates to a long-acting hydrogen release system for assisting cell transplantation as well as a preparation method and application thereof, belongs to the technical field of medical treatment, and provides a long-acting hydrogen release system for assisting cell transplantation in order to provide a substance capable of performing targeted delivery to a cell transplantation part and continuously releasing high-dose H2. The long-acting hydrogen release system comprises a hydrogen release material with a particle size of 5 nm to 10 [mu] m and a hydrogel matrix, and the cells are dispersed in the system; the concentration of the hydrogen release material is 0.01 to 100 [mu] g / mL, and the content of the cells is 10000 to 100000000 cells / mL. The long-acting hydrogen release system is used for maintaining the activity and directional differentiation of transplanted cells in an in-vitro differentiation / balling process and maintaining the activity and characteristics of the transplanted cells in a pathological microenvironment after transplantation. In a malignant pathological microenvironment, hydrogen is continuously supplied, so that the activity of stem cell spheres assembled / differentiated into cartilage cell microspheres and the hyaline cartilage phenotype are effectively maintained, and the activity of transplanted stem cells and the hyaline cartilage differentiation potential are maintained by continuously supplying hydrogen; and continuously supplying hydrogen to maintain the activity and transparency of the transplanted cartilage cells.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] The present application belongs to the technical field of medicine and medical technology, and particularly relates to a long-acting hydrogen-releasing system for assisting cell transplantation and a preparation method and application thereof. BACKGROUND

[0002] Cell transplantation is suitable for tissue / organ defects and metabolic disorder diseases that are difficult to self-repair, such as islet cell transplantation for diabetes, hepatocyte transplantation for acute liver failure, and cartilage / stem cell transplantation for cartilage defects. Among them, osteoarthritis is one of the most severe pathological microenvironments, which can easily cause the failure of cell transplantation for repairing articular cartilage defects. Generally, cartilage and tendon injuries can trigger cartilage degeneration and osteoarthritis progression, and the two form a vicious cycle, which is difficult to prevent or reverse in clinical practice.

[0003] Stem cell transplantation (SCT) has attracted much attention due to the extensive proliferation potential and multi-directional differentiation ability of stem cells, showing broad therapeutic prospects, but it is crucial to prevent accidental differentiation of stem cells in vivo. Autologous chondrocytes are difficult to expand in vitro and are prone to differentiate into fibrosis and hypertrophy phenotypes, affecting the quality of transplantation and long-term efficacy. In 14 clinical trials on autologous chondrocyte transplantation (ACT) for osteoarthritis treatment, only 5 showed better clinical effects than the control group, and the failure rate within 15 years was as high as 58.5%.

[0004] By combining the advantages of stem cells and ACT, autologous mesenchymal stem cells (MSCs) are isolated and differentiated into chondrocytes in vitro, and then transplanted, to solve the problem of limited cell expansion. In addition, assembling chondrocytes into microspheres (ACsT) and using matrix-assisted ACT (MACT) help to construct a cartilage-like transplant, which is beneficial to improve the bioavailability of chondrocytes. However, during the in vitro differentiation / spheroidization process, how to maintain the vitality and phenotype of cells is a major challenge to improve the transplantation effect. In addition, clinical cell transplantation also faces great challenges, that is, when encountering pathological microenvironments, transplanted cells often rapidly lose vitality and normal physiological properties, greatly limiting their clinical efficacy.

[0005] Targeted delivery and sustained release of high-dose H2 to the cell transplantation site is crucial for maximizing the cell protection effect of H2 in a severe pathological microenvironment. Scaffolds and hydrogels carrying hydrogen-producing materials are ideal ways to achieve local delivery of high-dose H2. For cartilage / bone repair, at least 2-3 months of time is usually required, but the H2 release duration of current hydrogen-producing materials does not exceed 7 days. Developing ultra-long-acting hydrogen-producing materials is of great significance to improve the effect of H2-assisted cartilage / bone repair, but it is also quite challenging. SUMMARY

[0006] One of the objectives of this invention is to provide a long-acting hydrogen release system for assisting cell transplantation. The long-acting hydrogen release system includes a hydrogen release material with a particle size of 5 nm-10 μm and a hydrogel matrix, wherein the cells are dispersed in the system; the concentration of the hydrogen release material is 0.01-100 μg / mL, and the cell content is 10,000-100,000,000 cells / mL.

[0007] The hydrogen-releasing material can be a nanosheet or any other shape. Preferably, the hydrogen-releasing material is a hydrogen-releasing material nanosheet with a thickness of 5-500 nm.

[0008] More preferably, the hydrogen-releasing material nanosheets are magnesium silicide nanosheets with a thickness of 10-150 nm; or the hydrogen-releasing material nanosheets are titanium silicide nanosheets with a thickness of 5-200 nm.

[0009] Furthermore, the hydrogel is the matrix material of the system and has photosensitive crosslinking, acoustic crosslinking, or thermosensitive crosslinking properties. Its components include, but are not limited to: methacrylamide gelatin / methacrylamide hyaluronic acid composite photosensitive hydrogel, sodium alginate ion-crosslinked hydrogel, chitosan / modified chitosan-based thermosensitive hydrogel, polyacrylate thermosensitive hydrogel, gelatin, fibrin hydrogel, hyaluronic acid-based hydrogel, polyethylene glycol-based hydrogel, etc.

[0010] Preferably, the hydrogel matrix can be a composite photosensitive hydrogel of methacrylamide gelatin and methacrylamide hyaluronic acid, wherein the mass ratio of methacrylamide gelatin to methacrylamide hyaluronic acid is 1-10:0-5.

[0011] If a photosensitive hydrogel is used, it should be supplemented with appropriate light irradiation, such as 5-60 seconds of ultraviolet light irradiation.

[0012] Furthermore, the hydrogen-releasing material is prepared from metal hydrides, metal silicides, metal borides, metal particles, metal alloys, and silicon powder, and its components include, but are not limited to: magnesium silicide, titanium silicide, calcium silicide, iron silicide, zirconium silicide, cerium silicide, calcium boride, magnesium boride, calcium hydride, magnesium hydride, magnesium, magnesium alloy, zinc alloy, iron alloy, silicon, silicon-magnesium alloy, and silicon hydride.

[0013] Furthermore, the cells in the cell transplantation are cell microspheres with a concentration of 1-1000 microspheres / mL; or the cells in the cell transplantation are a cell solution with a concentration of 10000-100000000 cells / mL.

[0014] Furthermore, the cell microspheres are chondrocyte microspheres or stem cell microspheres; the cell solution is chondrocytes or stem cells.

[0015] A second objective of this invention is to provide a method for preparing the aforementioned long-acting hydrogen release system for assisting cell transplantation, the method comprising the following steps:

[0016] The first step is to uniformly disperse the hydrogen-releasing material powder in a solvent, with a mass ratio of hydrogen-releasing material powder to solvent of 1:0.001-1:1000;

[0017] The second step is to transfer the material to a grinding instrument with inert gas protection and grind it to a suitable size of 5nm-10μm; the third step is to collect the initial product of the hydrogen-releasing material by centrifugation and wash the initial product to obtain the hydrogen-releasing material.

[0018] Step 4: Disperse the hydrogen-releasing material and cell microspheres or cell solution evenly in the hydrogel matrix to form a mixed hydrogel for cell transplantation therapy.

[0019] Preferably, in the first step, the hydrogen-releasing material powder is selected from one or more of the following: magnesium silicide, titanium silicide, calcium silicide, iron silicide, zirconium silicide, cerium silicide, calcium boride, magnesium boride, calcium hydride, magnesium hydride, magnesium, magnesium alloy, zinc alloy, ferroalloy, silicon, silicon-magnesium alloy, and silicon hydride. The components include, but are not limited to: magnesium silicide, titanium silicide, calcium silicide, iron silicide, zirconium silicide, cerium silicide, calcium boride, magnesium boride, calcium hydride, magnesium hydride, magnesium, magnesium alloy, zinc alloy, ferroalloy, silicon, silicon-magnesium alloy, and silicon hydride.

[0020] Furthermore, the solvent in the first step and the washing agent in the third step are one or more of methanol, ethanol, propanol, butanol, polyethylene glycol, ethylene glycol, glycerol, dimethylformamide, and dimethyl sulfoxide.

[0021] Preferably, in the fourth step, a mixed hydrogel of methacrylamide gelatin and methacrylamide hyaluronic acid in a mass ratio of 1-10:0-5 is used as a matrix, and then 0.01-100 μg / mL of hydrogen-releasing material nanosheets and cell microspheres or cell solution are co-loaded to form a mixed solution, which is then subjected to ultraviolet irradiation for 5-60 seconds to form the solution.

[0022] The purpose or application of the long-acting hydrogen release system is to assist in cell culture and transplantation in the treatment of osteoarthritis, nervous system diseases, digestive system diseases and skeletal system diseases.

[0023] In other words, the aforementioned long-acting hydrogen release system for assisting cell transplantation is used to continuously supply hydrogen to assist cell culture and transplantation in the treatment of osteoarthritis, nervous system diseases, digestive system diseases, and skeletal system diseases.

[0024] Furthermore, the aforementioned long-acting hydrogen release system is used to maintain the viability and directed differentiation of transplanted cells during in vitro differentiation / spheroidization, and to maintain the activity and characteristics of transplanted cells in the post-transplantation pathological microenvironment. In a malignant pathological microenvironment, this invention effectively maintains the activity and hyaline cartilage phenotype of stem cell spheres assembling / differentiating into chondrocyte microspheres by continuously supplying hydrogen, continuously supplying hydrogen to maintain the activity and hyaline cartilage differentiation potential of transplanted stem cells, and continuously supplying hydrogen to maintain the activity and hyaline properties of transplanted chondrocytes.

[0025] The beneficial effects of this invention are as follows:

[0026] 1. To maintain the viability and characteristics of transplanted cells in a pathological microenvironment.

[0027] In a malignant pathological microenvironment, continuous hydrogen supply effectively maintains the activity of stem cell spheres assembling / differentiating into chondrocyte microspheres and the hyaline cartilage phenotype. Continuous hydrogen supply also maintains the activity of transplanted stem cells and the differentiation potential of hyaline cartilage, as well as the activity and hyaline properties of transplanted chondrocytes.

[0028] 2. A novel hydrogel co-loaded with long-lasting hydrogen-releasing materials and chondrocyte microspheres enhances the efficiency of cartilage repair in osteoarthritis.

[0029] The magnesium silicide nanoplates provided by this invention have a hydrogen release time of 30 days; the titanium silicide nanosheets have a hydrogen release time of 60 days.

[0030] Based on the above findings, a novel hydrogel graft was further constructed, which ingeniously co-loads an ultra-long-lasting hydrogen-releasing material and chondrocyte microspheres / mesenchymal stem cell microspheres. Through in-situ, ultra-long-term hydrogen release, the activity and hyaline cartilage differentiation potential of the transplanted mesenchymal stem cells were effectively maintained, as well as the activity and hyaline properties of the transplanted chondrocytes.

[0031] Compared to hydrogels that only carry chondrocyte microspheres (i.e., simple cell therapy), the novel hydrogel (combined therapy) provided by this invention achieves co-loading of long-acting hydrogen-releasing materials and chondrocyte microspheres; this innovative design can not only precisely regulate the inflammatory microenvironment of bone and joints, but also significantly maintain the activity of transplanted chondrocytes and the unique properties of hyaline cartilage, thereby exhibiting a more powerful cartilage regeneration capacity.

[0032] Compared to hydrogels that rely solely on long-acting hydrogen release (i.e., hydrogen molecule therapy alone), this treatment overcomes the bottleneck of hydrogen molecules' lack of direct tissue regeneration capacity. It can not only regulate the inflammatory microenvironment of joints like long-acting hydrogen-releasing hydrogels, but also fully leverage the positive role of chondrocytes in promoting cartilage regeneration, achieving complementary advantages between the two. This results in a more outstanding cartilage repair effect for arthritis, providing a better treatment option for patients with osteoarthritis. Attached Figure Description

[0033] Figure 1 Figure a shows a schematic diagram of cell culture during the spheroidization and differentiation process of stem cells. Figure b shows a bright-field image of CMS (chondrocyte microspheres) after 21 days of culture in a conventional incubator and a hydrogen incubator, as well as images of TUNEL (apoptosis), Live (living), Dead (dead), Co2 (type II collagen), Col1 (type I collagen), MMP13 (matrix metalloproteinase 13), Col10 (type 10 collagen), and toluidine blue (b). Figure c shows the corresponding statistical analysis graph. Figure 2 This diagram illustrates the 7-day culture period of CMS (chondrocyte microspheres) using diluted clinical osteoarthritis synovial fluid in a conventional incubator and an H2 incubator, along with representative bright-field and serial fluorescence validation results and corresponding statistical analysis graphs.

[0034] Figure 3 The effects of H2 culture on the IL-1β-induced OA chondrocyte phenotype are shown in (a, b); the effects of different treatments on the differentiation of SCM (stem cell microspheres) in SCM@Gel after 7 days of culture are shown in (c, d).

[0035] Figure 4 SEM images (a, c) and hydrolysis hydrogen production curves (b, d) of magnesium silicide nanosheets MSN (a, b) and titanium silicide nanosheets TSN (c, d) of the same size.

[0036] Figure 5 Atomic force microscopy images (a) and corresponding size analysis (b) of TSN (titanium silicide nanosheets) and TiSi2 are shown respectively. XRD pattern of raw (titanium silicide sodium powder) (c), H2 release behavior of TSN and TSN@Gel in PBS (pH=7.4) buffer containing 50 μg / mL TSN (d), schematic diagram of TSN / CMS@Gel incubated with synovial fluid of clinical osteoarthritis (e), schematic diagram of Live / Dead cells, ROS (reactive oxygen species), TUNEL (apoptosis) (g), IL-1β (interleukin-1β) and TNF-α (tumor necrosis factor-α) (h), Bcl2 (leukemia-2 gene) and Bcl6 (leukemia-6 gene) (i), Col2 (type II collagen) and Col10 (type 10 collagen) (j), fluorescence images and corresponding statistical analysis of MMP13 (matrix metalloproteinase 13) and Col1 (type 1 collagen) (k), relative mRNA levels after 7 days of incubation with human osteoarthritis synovial fluid in a conventional incubator (l).

[0037] Figure 6This paper presents the design, preparation, and characterization of MSN / SCM@Gel (magnesium silicate nanosheets / mesenchymal stem cell microspheres @ 9.5% methacrylamide gelatin (GelMA) and 0.5% methacrylamide hyaluronic acid (HAMA) mixed hydrogel). The images show: representative scanning electron microscope (SEM) images of magnesium silicate nanosheets (MSN) (a); atomic force microscope (AFM) images of magnesium silicate nanosheets and their corresponding size analysis (b, c); elemental distribution map of magnesium silicate nanosheets (d); hydrolytic H2 release behavior of MSN and MSN@Gel in PBS solution at pH 7.4 (e), showing that they maintained a high release rate even after 28 days; and different concentrations of MSN (…). The effect of MSN concentrations of 25, 50, 100, 200, 400, and 800 μm / ml on the pH of PBS solution (f). Although the pH increased continuously during hydrolysis, it did not exhibit physiological toxicity. Cell compatibility tests of MSN and MSO on chondrocytes and adipose-derived stem cells (ADSCs) (g) showed that MSN and MSO had high compatibility over a wide concentration range. Preparation method of MSN / SCM@Gel (h). Effect of MSN concentration on gelation time (i) and effect of SCM content on cell viability in MSN / SCM@gel containing 100 μg / mL MSN (j). Figure 7 The diagram shows the MSN / SCM@Gel experiment (a); after 7 days of treatment with different gels (Gel, MSO@Gel, MSN@Gel, SCM@Gel, MSO / SCM@Gel and MDN / SCM@Gel), the representative ROS (reactive oxygen species) / TUNEL (apoptosis) / SA-β-Gal (senescence-associated β-galactosidase) / Col (type II collagen) / Bcl2 (leukemia-2 gene) / p16 (cyclin 16) / Col10 (type I collagen) / IL-1β (interleukin 1β) / Col1 (type I collagen) Fluorescence images of collagen and corresponding quantitative analysis (b, c); representative ROS (reactive oxygen species), TUNEL (apoptosis), Live (living cells), Dead (dead cells), Col1 (type 1 collagen), Col2 (type 2 collagen), IL-1β (interleukin 1β), and Col10 (type 10 collagen) fluorescence images and corresponding quantitative analysis results of SCM (mesenchymal stem cell microspheres) after 21 days of co-culture in different gels (CM@Gel, MSO / SCM@Gel and MDN / SCM@Gel); cytokine levels in the culture medium (f).

[0038] Figure 8To demonstrate that MSN / SCM@Gel effectively repaired critical-sized cartilage defects in rat joints with osteoarthritis three months after transplantation. The figures show: (a) a representative digital photograph of a rat joint with cartilage defects (red circle); (b) a micro-computed tomography (μCT) image; (c) a cross-sectional μCT image (red circle indicates the osteophyte growth site); (d) SOFG-stained image of cartilage tissue; (e) hematoxylin-eosin (HE)-stained image of cartilage tissue; (f) the maximum osteophyte growth; and (f)-(i) DJD, OARSI, and Mankin scores at the defect site three months after treatment.

[0039] Figure 9 This indicates that after 6 months of transplantation, TSN / CMS@Gel effectively repaired cartilage defects in sheep with osteoarthritis by locally activating CMS. Detailed Implementation

[0040] The present invention will be further explained and described below with reference to the accompanying drawings.

[0041] Example 1

[0042] Magnesium silicide nanosheets and titanium silicide nanosheets were prepared by ball milling under inert atmosphere combined with gradient centrifugation.

[0043] 30 mg of magnesium silicide or titanium silicide raw powder was dispersed in 10 mL of ethanol, then transferred to a grinding bottle and grinding instrument with argon protection. After grinding for 3 hours, magnesium silicide or titanium silicide nanosheets were collected by gradient centrifugation and washed three times with ethanol.

[0044] Example 2

[0045] Magnesium silicide nanosheets were used to prepare a long-lasting hydrogen release system for use in cell transplantation.

[0046] The method is as follows: A mixed hydrogel of 9.5% methacrylamide gelatin (GelMA) and 0.5% methacrylamide hyaluronic acid (HAMA) was used as a matrix, and 100 μg / mL of hydrogen-releasing material (magnesium silicide nanosheets) and 400 spheres / mL of cell microspheres were co-loaded to form a mixed solution. Then, the mixture was irradiated with ultraviolet light for 15 seconds to form a novel graft (the cell microspheres formed a mixed solution dispersed in a long-lasting hydrogen-releasing system).

[0047] Figure 6The image shows the design, preparation, and characterization of MSN / SCM@Gel (magnesium silicate nanosheets / mesenchymal stem cell microspheres @ 9.5% methacrylamide gelatin (GelMA) and 0.5% methacrylamide hyaluronic acid (HAMA) mixed hydrogel). The images are as follows: representative scanning electron microscope images of magnesium silicate nanosheets (a); atomic force microscope images of magnesium silicate nanosheets and their corresponding size analysis (b, c); elemental distribution map of magnesium silicate nanosheets (d); hydrolysis H2 release behavior of MSN and MSN@Gel in PBS solution at pH 7.4 (e), which still maintains a high release rate after 28 days; and the effect of different MSN concentrations (25, 50, 100, 200, 400, and 800 μm / ml) on the pH of the PBS solution after hydrolysis (f). The pH value increased continuously but showed no physiological toxicity. Cell compatibility tests (g) of MSN and MSO on chondrocytes and adipose-derived stem cells (ADSCs) showed high compatibility of MSN and MSO over a wide concentration range. The preparation method of MSN / SCM@Gel was described (h). The effect of MSN concentration on gelation time (i) and the effect of SCM content on cell viability in MSN / SCM@gel containing 100 μg / mL MSN were investigated (j). After weighing the co-loading concentration and gelation time, 100 μg / mL of hydrogen-releasing material and 100 microspheres / mL of cell microspheres were ultimately selected. MSN, MSO, SCM, and Gel refer to magnesium silicide nanosheets, magnesium silicide nanosheet hydrolysate, stem cell microspheres, and GelMA / HAMA hydrogel, respectively.

[0048] Example 3

[0049] By transplanting the graft from Example 2, MSN / SCM@Gel was used to achieve efficient repair of cartilage defects in a rat model of osteoarthritis.

[0050] A rat model of osteoarthritis with cartilage defects was established: a medial patellar skin incision was made at the knee joint, and the joint cavity was exposed after patellar dislocation. The anterior cruciate ligament was severed using surgical scissors, and the knee was then flexed to 90 degrees. Force was applied to the tibia from the posterior to the anterior side of the knee to observe the displacement of the tibia relative to the femur to verify the success of the surgery. Finally, the joint was flushed with sterile saline and then sutured. Rats were housed in a free-moving environment for 21 days to induce osteoarthritis. Subsequently, cartilage defect surgery was performed, exposing the joint cavity using the same surgical procedure. A 1.5 mm diameter cartilage defect was created at the trochlear groove using a sterile needle. A novel graft designed as described above was then transplanted. On day 90, all rats were sacrificed by cervical vertebrae resection for μCT analysis, histopathological staining, and gait analysis. The appearance of each joint was recorded with a camera and scored according to the macroscopic scoring guidelines recommended by Mankin, DJD (Degenerative Joint Disease Scale), and OARSI (Organization for the Study of Osteoarthritis International).

[0051] Figure 8 The results show that three months after transplantation, MSN / SCM@Gel effectively repaired critical-sized cartilage defects in rat joints with osteoarthritis. The figures are as follows: (a) a representative digital photograph of a rat joint with cartilage defects (red circles); (b) a micro-computed tomography (μCT) image; (c) a cross-sectional μCT image (red circles indicate osteophyte growth); (d) SOFG staining image of cartilage tissue; (e) hematoxylin-eosin (HE) staining image of cartilage tissue; (f) maximum osteophyte growth; and (f)-(i) DJD, OARSI, and Mankin scores of the defect site three months after treatment. MSN / SCM@Gel treatment demonstrated excellent therapeutic effects, including significantly remodeling the malignant OA microenvironment, preventing cartilage degeneration, inhibiting osteophyte growth, promoting the directional differentiation of SCM into hyaline cartilage, and regenerating uniform, smooth cartilage tissue with normal cell density, sufficient glycosaminoglycans, and perfect integration with adjacent cartilage tissue. MSN, MSO, SCM, and Gel refer to magnesium silicide nanosheets, magnesium silicide nanosheet hydrolysis products, stem cell microspheres, and GelMA / HAMA hydrogel, respectively.

[0052] Example 4

[0053] By transplanting the graft from Example 2, TSN / CMS@Gel was used to achieve efficient repair of cartilage defects in a sheep model of osteoarthritis.

[0054] A cartilage defect model of osteoarthritis in sheep was induced by creating four cylindrical, full-thickness cartilage defects, each 0.5–0.8 mm deep (the exact depth depends on the precise location) and 4 mm in diameter, on each of the two femoral condyles. The sheep were then allowed free movement for two months without any mechanical support. Subsequently, two months after the initial defect creation, the damaged cartilage tissue was debrided and enlarged to a diameter of 6 mm and a depth of 1 mm using a biopsy needle. The novel graft solution was then locally injected into the defect, followed by 30 seconds of ultraviolet irradiation, and finally fixed to the surrounding cartilage with bioglue.

[0055] Fifteen and thirty days after transplantation, some sheep were euthanized, and the grafts were then extracted for live / dead staining and imaging to determine chondrocyte survival. Six months after transplantation, defective joint tissue was harvested for histological analysis and joint scoring, and synovial fluid was collected to determine its volume and cytokine levels.

[0056] Figure 9This indicates that after 6 months of transplantation, TSN / CMS@Gel effectively repaired cartilage defects in sheep osteoarthritis by locally activating CMS. The figures show: (a) a schematic diagram of sheep osteoarthritis model construction, TSN / CMS@Gel transplantation process, and therapeutic effect characterization; (b) Safranin O and Fast Green staining of normal and model cartilage tissues 60 days after induction of osteoarthritis; (c) live / dead fluorescence images of grafts removed 15 and 30 days after transplantation and the corresponding survival rate of transplanted chondrocytes; (e) a representative digital photograph of sheep joints with two osteoarthritis cartilage defects 6 months after treatment and the corresponding residual cartilage defect area; (f) SO-FG staining of cartilage tissue at the defect site 6 months after treatment (g) and the corresponding Mankin score; (h) glycosaminoglycan content (i) and synovial fluid volume at the defect site 6 months after treatment; and (k) statistical results of joint spatial distance on representative joint X-ray images and the levels of six cytokines in the synovial fluid 6 months after treatment (m). Data from the normal group in Figure 1 were collected from normal sheep before the establishment of the osteoarthritis model, while data from the other groups were collected six months after treatment (day 240). As shown in Figures c and d, in the group without the hydrogen-releasing material CMS@Gel, the chondrocyte survival rate was only 20.5±4.2% on day 15 and only 14.8±3.8% on day 30, confirming the rapid inactivation of transplanted chondrocytes in the osteoarthritis microenvironment. In contrast, in the group with the hydrogen-releasing material TSN / CMS@Gel, the chondrocyte survival rate was as high as 85.5±11.4% on day 15, and remained at 75.4±9.1% on day 30. This high cell survival rate (i.e., high cell viability retention efficiency) of TSN / CMS@Gel transplantation will greatly benefit the repair of cartilage defects. Six months post-transplantation, representative digital images and corresponding statistical data in Figures e and f showed particularly significant cartilage regeneration after TSN / CMS@Gel treatment, as most cartilage defect areas were repaired, demonstrating a considerably high cartilage defect repair efficiency in osteoarthritis (70.6 ± 15.6%). As shown in Figure g (SO-FG results), the cartilage defect area was filled with abundant and uniform proteoglycans, and the newly formed cartilage was structurally orderly with uniform cell arrangement, resembling the surrounding normal cartilage (Figure g). The corresponding Mankin score also confirmed the effective repair of cartilage defects by TSN / CMS@Gel transplantation. Figure 6h). Furthermore, the GAG ​​content in the newly formed cartilage in the TSN / CMS@Gel group was significantly higher than that in the CMS@Gel and model groups, and approached the content of normal cartilage (Figure i). In summary, these results confirm that TSN / CMS@Gel transplantation significantly enhances the repair of critical-sized cartilage defects in a sheep model of osteoarthritis. Moreover, 6 months of TSN / CMS@Gel treatment almost completely reversed the progression of osteoarthritis caused by cartilage defects, as synovial fluid volume, joint space distance, and inflammatory cytokine levels all returned to near-normal levels. MSN, CMS, and Gel refer to titanium silicide nanosheets, cartilage microspheres, and GelMA hydrogel, respectively.

[0057] Example 4

[0058] Please refer to Figure 1 Figure a shows a schematic diagram of cell culture during the process of stem cell spheroidization and differentiation. In this embodiment, stem cell spheroidization and differentiation were carried out in a General incubator (5% carbon dioxide, 21% oxygen and 74% nitrogen) and a Hydrogen incubator (5% carbon dioxide, 21% oxygen, 60% hydrogen and 14% nitrogen). Figure b shows a bright-field image of CMS after 21 days of culture, as well as images of TUNEL (apoptosis), Live (living), Dead (dead), Col2 (type II collagen), Col1 (type I collagen), MMP13 (matrix metalloproteinase 13), Col10 (type 10 collagen), and toluidine blue. Figure c shows the corresponding statistical analysis, indicating that H2 can maintain the viability and transparent phenotype of chondrocyte microspheres (CMS) during the formation of stem cell spheroids and differentiation into chondrocytes.

[0059] Please refer to Figure 2 The diagram above shows the incubation of CMS in a conventional incubator and an H2 incubator using diluted clinical osteoarthritis synovial fluid during the 7-day culture period (top left). Representative bright-field data (bottom) and a series of fluorescence validation results from both culture modes, along with corresponding statistical analysis, are also shown (top right). This indicates that H2 can maintain the viability and transparent phenotype of CMS during co-incubation with human osteoarthritis synovial fluid.

[0060] Please refer to Figure 3 The effects of H2 culture on the IL-1β-induced OA chondrocyte phenotype were investigated (a, b); the effects of different treatments on the differentiation of chondrocytes with stem cell microspheres in SCM@Gel after 7 days of culture were also investigated (c, d). It can be seen that H2 can reverse the morphology of OA chondrocytes, causing them to transform into a hyaline cartilage phenotype, and correcting the induction of SCM (mesenchymal stem cell microspheres) into hyaline cartilage differentiation in the OA microenvironment.

[0061] Please refer to Figure 4 This study investigated the effect of hydrogen-releasing materials of different sizes on hydrogen release. SEM images (a, c) and hydrolysis hydrogen production curves (b, d) of magnesium silicide nanosheets (MSN) (a, b) and titanium silicide nanosheets (TSN) (c, d) of different sizes are shown. The sizes of the magnesium silicide nanosheets (MSN) are MSN-150 (width 150 nm, thickness 10 nm), MSN-225 (width 225 nm, thickness 25 nm), MSN-300 (width 300 nm, thickness 50 nm), MSN-375 (width 375 nm, thickness 100 nm), and MSN-450 (width 450 nm, thickness 150 nm). The sizes of the titanium silicide nanosheets (TSN) are TSN100 (width 100 nm, thickness 5 nm), TSN200 (width 200 nm, thickness 10 nm), TSN100 (width 1000 nm, thickness 200 nm), and TSN100 (width 5000 nm, thickness 2000 nm). In this experiment, the thickness of the nanosheets had a decisive influence on the hydrogen production time. The smaller the thickness, the better the hydrogen release effect. When the size of MSN was below 450 nm, the hydrogen release effect was very good. The production time of magnesium silicide nanosheet MSN could be maintained for at least 21 days, while the thickness of titanium silicide nanosheet TSN was at least 90 days when it was 200 nm. Although hydrogen could also be released at 1000 nm, the concentration was low. The 90-day maintenance time is the longest hydrogen release time reported to date.

[0062] Figure 5 Atomic force microscopy images (a) and corresponding size analysis (b) of TSN (titanium silicide nanosheets) and TiSi2 are shown below. XRD pattern of raw (titanium silicide sodium powder) (c), H2 release behavior of TSN and TSN@Gel in PBS (pH=7.4) buffer containing 50 μg / mL TSN (d), schematic diagram of TSN / CMS@Gel incubated with synovial fluid of clinical osteoarthritis (e), schematic diagram of Live / Dead cells, ROS (reactive oxygen species), TUNEL (apoptosis) (g), IL-1β (interleukin-1β) and TNF-α (tumor necrosis factor-α) (h), Bcl2 (leukemia-2 gene) and Bcl6 (leukemia-6 gene) (i), Col2 (type II collagen) and Col10 (type 10 collagen) (j), fluorescence images and corresponding statistical analysis of MMP13 (matrix metalloproteinase 13) and Col1 (type 1 collagen) (k), relative mRNA levels after 7 days of incubation with human osteoarthritis synovial fluid in a conventional incubator (l). This demonstrates that the TSN / CMS@Gel (titanium silicide nanosheets / chondrocyte microspheres@Gel hydrogel) graft can continuously release hydrogen gas, thereby protecting the viability and transparency of CMS (chondrocyte microspheres) in the synovial fluid of the knee joint of patients with osteoarthritis in in vitro experiments.

[0063] Figure 7 The diagram shows the MSN / SCM@Gel experiment (a); after 7 days of treatment with different gels (Gel, MSO@Gel, MSN@Gel, SCM@Gel, MSO / SCM@Gel and MSN / SCM@Gel), the representative ROS (reactive oxygen species) / TUNEL (apoptosis) / SA-β-Gal (senescence-associated β-galactosidase) / Col (type II collagen) / Bcl2 (leukemia-2 gene) / p16 (cyclin 16) / Col10 (type I collagen) / IL-1β (interleukin 1β) / Col1 (type I) Fluorescence images and corresponding quantitative analyses of type 1 collagen (b, c); representative ROS (reactive oxygen species), TUNEL (apoptosis), Live (living cells), Dead (dead cells), Col1 (type 1 collagen), Col2 (type 2 collagen), IL-1β (interleukin 1β), and Col10 (type 10 collagen) fluorescence images and corresponding quantitative analyses of SCM (mesenchymal stem cell microspheres) after 21 days of co-culture in different gels (SCM@Gel, MSO / SCM@Gel, and MSN / SCM@Gel); cytokine levels in the culture medium (f). MSN, MSO, SCM, and Gel refer to magnesium silicate nanosheets, magnesium silicate nanosheet hydrolysate, stem cell microspheres, and GelMA / HAMA hydrogel, respectively. MSN / SCM@Gel can reverse osteoarthritis chondrocytes to a hyaline-like cell phenotype, thereby maintaining the hyaline cartilage differentiation process of encapsulated SCM cells.

Claims

1. A long-acting hydrogen release system for assisting cell transplantation, characterized in that, The long-lasting hydrogen release system includes a hydrogel matrix, hydrogen-releasing materials with a particle size of 5nm-10μm, and the cells are dispersed in the system; the content of the hydrogen-releasing material is 0.01-100μg / mL, and the cell content is 10000-100000000 cells / mL.

2. The long-acting hydrogen release system for assisting cell transplantation as described in claim 1, characterized in that, The hydrogel is the matrix material of the system, and its components include one or more of the following: methacrylated gelatin / methacrylated hyaluronic acid composite photosensitive hydrogel, sodium alginate ion crosslinking hydrogel, chitosan / modified chitosan-based thermosensitive hydrogel, polyacrylate thermosensitive hydrogel, gelatin, fibrin hydrogel, hyaluronic acid-based hydrogel, and polyethylene glycol-based hydrogel.

3. The long-acting hydrogen release system for assisting cell transplantation as described in claim 1, characterized in that, The cells used in the cell transplantation are cell microspheres with a concentration of 1-1000 microspheres / mL, and each microsphere contains 1000-200000000 cells; or the cells used in the cell transplantation are cell solutions with a concentration of 10000-100000000 cells / mL.

4. The long-acting hydrogen release system for assisting cell transplantation as described in claim 3, characterized in that, The cell microspheres are chondrocyte microspheres or stem cell microspheres; the cell solution is chondrocytes or stem cells.

5. The method for preparing the long-acting hydrogen release system for assisting cell transplantation as described in any one of claims 1-4, characterized in that, The preparation method includes the following steps: The first step is to uniformly disperse the hydrogen-releasing material powder in a solvent, with a mass ratio of hydrogen-releasing material powder to solvent of 1:0.001-1:1000; The second step is to transfer the material to a grinding instrument with inert gas protection and grind it to a size of 5nm-10μm. The third step is to centrifuge and collect the initial product of the hydrogen-releasing material, and then wash the initial product to obtain the hydrogen-releasing material. Step 4: Disperse the hydrogen-releasing material and cell microspheres or cell solution evenly in the hydrogel matrix to form a mixed hydrogel.

6. The method for preparing the long-acting hydrogen release system for assisting cell transplantation as described in claim 5, characterized in that, The hydrogen-releasing material powder is selected from one or more of the following: metal hydrides, metal silicides, metal borides, metal microparticles, metal alloys, and silicon powder.

7. The method for preparing the long-acting hydrogen release system for assisting cell transplantation as described in claim 6, characterized in that, The hydrogen-releasing material powder is selected from one or more of the following: magnesium silicide, titanium silicide, calcium silicide, iron silicide, zirconium silicide, cerium silicide, calcium boride, magnesium boride, calcium hydride, magnesium hydride, magnesium, magnesium alloy, zinc alloy, iron alloy, silicon, silicon-magnesium alloy, and silicon hydride.

8. The method for preparing the long-acting hydrogen release system for assisting cell transplantation as described in claim 5, characterized in that, The solvent in the first step and the washing agent in the third step are one or more of methanol, ethanol, propanol, butanol, polyethylene glycol, ethylene glycol, glycerol, dimethylformamide, and dimethyl sulfoxide.

9. The application of the long-acting hydrogen release system for assisting cell transplantation as described in any one of claims 1-4, characterized in that, The aforementioned long-acting hydrogen release system is used to assist in cell culture and transplantation in the treatment of osteoarthritis, nervous system diseases, digestive system diseases, and skeletal system diseases.

10. The application as described in claim 9, characterized in that, The aforementioned long-acting hydrogen release system is used to maintain the activity and properties of transplanted cells during in vitro differentiation / spheroidization and in the post-transplantation pathological microenvironment.